Rukman R. Thota

Rukman R. Thota

Auto-generated profile, based on publicly available information

Rukman R. Thota

Division of Developmental Immunology, La Jolla Institute for Immunology, La Jolla, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2023 in Nature Immunology
Verified
Journal Article
Open access
PDF file
SBSpencer E. Brightman
Spencer E. Brightman
ABAngelica Becker
Angelica Becker
RTRukman R. Thota
Rukman R. Thota
MNMartin S. Naradikian
Martin S. Naradikian
LCLeila Chihab
Leila Chihab
SSStephen P. Schoenberger
Stephen P. Schoenberger
CD4+T cells play key roles in a range of immune responses, either as direct effectors or through accessory cells, including CD8+T lymphocytes. In cancer, neoantigen (NeoAg)-specific CD8+T cells capable of direct tumor recognition have been extensively studied, whereas the role of NeoAg-specific CD4+T cells is less well understood. We have characterized the murine CD4+T cell response against a validated NeoAg (CLTCH129>Q) expressed by the MHC-II-deficient squamous cell carcinoma tumor model (SCC VII) at the level of single T cell receptor (TCR) clonotypes and in the setting of adoptive immunotherapy. We find that the natural CLTCH129>Q-specific repertoire is diverse and contains TCRs with distinct avidities as measured by tetramer-binding assays and CD4 dependence. Despite these differences, CD4+T cells expressing high or moderate avidity TCRs undergo comparable in vivo proliferation to cross-presented antigen from growing tumors and drive similar levels of therapeutic immunity that is dependent on CD8+T cells and CD40L signaling. Adoptive cellular therapy (ACT) with NeoAg-specific CD4+T cells is most effective when TCR-engineered cells are differentiated ex vivo with IL-7 and IL-15 rather than IL-2 and this was associated with both increased expansion as well as the acquisition and stable maintenance of a T stem cell memory (TSCM)-like phenotype in tumor-draining lymph nodes (tdLNs). ACT with TSCM-like CD4+T cells results in lower PD-1 expression by CD8+T cells in the tumor microenvironment and an increased frequency of PD-1+CD8+T cells in tdLNs. These findings illuminate the role of NeoAg-specific CD4+T cells in mediating antitumor immunity via providing help to CD8+T cells and highlight their therapeutic potential in ACT.

28 February 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
AMAaron M. Miller
Aaron M. Miller
ZKZeynep Koşaloğlu-Yalçın
Zeynep Koşaloğlu-Yalçın
LWLuise Westernberg
Luise Westernberg
LMLeslie Montero
Leslie Montero
MBMilad Bahmanof
Milad Bahmanof
SSStephen P. Schoenberger
Stephen P. Schoenberger
The clinical impact of tumor-specific neoantigens as both immunotherapeutic targets and biomarkers has been impeded by the lack of efficient methods for their identification and validation from routine samples. We have developed a platform that combines bioinformatic analysis of tumor exomes and transcriptional data with functional testing of autologous peripheral blood mononuclear cells (PBMCs) to simultaneously identify and validate neoantigens recognized by naturally primed CD4 + and CD8 + T cell responses across a range of tumor types and mutational burdens. The method features a human leukocyte antigen (HLA)–agnostic bioinformatic algorithm that prioritizes mutations recognized by patient PBMCs at a greater than 40% positive predictive value followed by a short-term in vitro functional assay, which allows interrogation of 50 to 75 expressed mutations from a single 50-ml blood sample. Neoantigens validated by this method include both driver and passenger mutations, and this method identified neoantigens that would not have been otherwise detected using an in silico prediction approach. These findings reveal an efficient approach to systematically validate clinically actionable neoantigens and the T cell receptors that recognize them and demonstrate that patients across a variety of human cancers have a diverse repertoire of neoantigen-specific T cells.

24 January 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
SBSpencer E. Brightman
Spencer E. Brightman
MNMartin S. Naradikian
Martin S. Naradikian
RTRukman R. Thota
Rukman R. Thota
ABAngelica Becker
Angelica Becker
LMLeslie Montero
Leslie Montero
SSStephen P. Schoenberger
Stephen P. Schoenberger
CD4 + T cells play a critical role in antitumor immunity via recognition of peptide antigens presented on MHC class II (MHC-II). Although some solid cancers can be induced to express MHC-II, the extent to which this enables direct recognition by tumor-specific CD4 + T cells is unclear. We isolated and characterized T cell antigen receptors (TCRs) from naturally primed CD4 + T cells specific for 2 oncoproteins, HPV-16 E6 and the activating KRAS G12V mutation, from patients with head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma, respectively, and determined their ability to recognize autologous or human leukocyte antigen–matched antigen-expressing tumor cells. We found in both cases that the TCRs were capable of recognizing peptide-loaded target cells expressing the relevant MHC-II or B cell antigen-presenting cells (APCs) when the antigens were endogenously expressed and directed to the endosomal pathway but failed to recognize tumor cells expressing the source protein even after induction of surface MHC-II expression by IFN-γ or transduction with CIITA. These results suggest that priming and functional recognition of both a nuclear (E6) and a membrane-associated (KRAS) oncoprotein are predominantly confined to crosspresenting APCs rather than via direct recognition of tumor cells induced to express MHC-II.

29 April 2026 in Nature
Verified
Journal Article
Open access
PDF file
AFAmy C. Fan
Amy C. Fan
RTRukman R. Thota
Rukman R. Thota
NSNina Serwas
Nina Serwas
VVVivasvan S. Vykunta
Vivasvan S. Vykunta
KMKyle Marchuk
Kyle Marchuk
MKMatthew F. Krummel
Matthew F. Krummel
An effective immune system must sample and develop healthy self-identity to prevent autoimmunity and to discern pathogenic insults 1–3 . Self-proteins are presented to T cells in the thymus during immune cell development 2,3 and must be presented throughout the body to maintain regulatory T cell populations 4–6 and to provide tonic signals to sustain conventional T cells over time 7–9 . Observations of continuous apoptosis in some organs together with the ingestion of that material by myeloid populations has led to a conventional understanding of ongoing cell death as a major source of self-antigens 10 . Here we used a series of companion imaging and vesicular labelling technologies to reveal an alternative process undertaken by macrophages that results in non-destructive, direct sampling of living cells. This process requires cell–cell contact, does not require caspase activation and occurs via trogocytosis-like stretching of the target cell into the macrophage, which leads to the generation of submicrometre-sized vesicles that contain cytoplasm. Using a high-dimensional flow-based method for labelling vesicles, we demonstrate that live-sampled material is distinctly processed and is poorly subjected to fusion with lysosomes. The material also produces differential effects on the presentation of antigen to CD4 T cells compared with CD8 T cells. Disruption of this trafficking by redirecting antigen to the lysosome significantly reduced the associated macrophage-mediated priming of CD8 T cells. These results demonstrate an important and substantial sampling of living cells by the immune system, with clear consequences for maintaining the border of immunity.

16 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
AFAmy C. Fan
Amy C. Fan
RTRukman Thota
Rukman Thota
NSNina Serwas
Nina Serwas
VVVivasvan S. Vykunta
Vivasvan S. Vykunta
KMKyle Marchuk
Kyle Marchuk
MKMatthew F. Krummel
Matthew F. Krummel
SUMMARY PARAGRAPH: An effective immune system must sample and appreciate healthy-self identity to prevent autoimmunity and to contrast to pathogenic insults 1–3 . Self-proteins are presented to T cells in the thymus during immune cell development 2,3 , and must be presented throughout the body to both maintain regulatory T cell populations 4–6 and provide a tonic signal to maintain conventional T cells over time 7–9 . The ready observations of continuous apoptosis in some organs together with the ingestion of that material by myeloid populations has led to a conventional understanding of ongoing cell-death as a major source of self-antigens 10 , complemented in some situations by uptake of free-floating cell-derived vesicles. Here, we used a series of companion imaging and vesicular labeling technologies to reveal an alternate process undertaken by macrophages that results in non-destructive and direct sampling of living cells. The process requires cell-cell contact, does not require caspase activation, and takes place via a trogocytosis-like stretching of the target cell into the macrophage, leading to the generation of submicron-sized vesicles containing cytoplasm. Using a high-dimensional flow-based method for labeling vesicles ingested under this versus other conditions, we find that live-sampled material is distinctly processed, is poorly subject to fusion with lysosomes, and produces ensuing differential effects on the presentation of those to CD4 versus CD8 T cells. Disrupting this trafficking by redirecting antigen to the lysosome significantly reduced the associated macrophage-mediated priming of CD8 T cells. This demonstrates an important and substantial sampling of living cells by the immune system, with clear consequences for maintaining the border of immunity.

18 July 2023 in Nature Immunology
Verified
Journal Article
Open access
PDF file
SBSpencer E. Brightman
Spencer E. Brightman
ABAngelica Becker
Angelica Becker
RTRukman R. Thota
Rukman R. Thota
MNMartin S. Naradikian
Martin S. Naradikian
LCLeila Chihab
Leila Chihab
SSStephen P. Schoenberger
Stephen P. Schoenberger